DexCom has lagged behind the Dow Jones over the past year, yet analysts remain highly bullish about the stock’s outlook.

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...

DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...

Shares of diabetes management equipment provider DexCom (NASDAQ: DXCM) had tumbled 17% by 11:15 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The culprit was the ...

DexCom, Inc. DXCM is well-positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong first-quarter 2026 ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

DexCom is a major player in the continuous glucose monitoring (CGM) market. These devices help diabetes patients monitor their blood sugar levels in real time throughout the day, an activity that is ...

DexCom, Inc. (DXCM Quick Quote DXCM - Free Report) reported first-quarter 2025 adjusted earnings per share (EPS) of 32 cents, which missed the Zacks Consensus Estimate of 33 cents by 3%. The company ...

DexCom (DXCM Quick Quote DXCM - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...